Assessment & Adherence

Psychopharmacology

Psychotic Disorders

Industry-Supported Symposia: Improving Long-Term Outcomes in Schizophrenia: Translating Evidence to Practice

Friday, October 26
7:00 AM - 9:00 AM
Location: Valencia W415 A

Breakfast will be served. Seating for these sessions is available on a first come, first served basis only. Admittance is based on availability and is not guaranteed. Please plan to arrive early to ensure a seat. Breakfast will only be available until 8 AM.

Nonadherence to antipsychotics is a significant concern, with rates estimated as high as 50%, attributable to such factors as limited access to mental health care, a lack of coordinated transitions between care settings, and the complexity of therapeutic regimens. Long-acting injectable antipsychotics (LAIAs) have emerged as a valuable tool to simplify treatment and improve adherence; however, their effective implementation in practice requires that psychiatrists and allied health care providers have a thorough understanding of the strengths and limitations of available LAIAs as well as strategies to overcome barriers to their initiation and continued use. Drs. Melnick and Tandon will examine the latest clinical evidence regarding LAIAs and demonstrate how to translate it into informed individualized treatment selection and management in patients with schizophrenia.

Supported by educational grants from Alkermes, Inc., Indivior Inc, and Otsuka America Pharmaceutical, Inc. and Lundbeck.

Ilan Melnick, MD

Chief Medical Officer, Passageway Residences of Dade County, Miami, Florida

Ilan Melnick, MD, is the primary psychiatrist in two outpatient clinics in the Miami, Florida area, as well as a staff psychiatrist and Chief Medical Officer at Passageway Residences of Miami-Dade County. In addition, Dr. Melnick is a staff psychiatrist and Medical Director for Jewish Community Services and performs independent medical and psychiatric evaluations for Miami-Dade County police, fire, transit and aviation departments.

Dr. Melnick received his medical degree from the Universidad Central del Caribe in Bayamon, Puerto Rico and went on to do his residency in psychiatry and fellowship in geriatric psychiatry at the University of Miami/Jackson Memorial Hospital. He continues to be involved in education through his role giving grand rounds at major universities and hospitals around the world.

Presentation(s):

Send Email for Ilan Melnick

Rajiv Tandon, MD

Professor of Psychiatry, Department of Psychiatry, University of Florida, Gainesville, Florida

Rajiv Tandon, MD, is Professor of Psychiatry at the University of Florida College of Medicine in Gainesville, Florida. Dr. Tandon has authored more than 300 scientific publications and given over 1,000 national and international scientific presentations. He has received several awards for research and teaching in schizophrenia, including the 2010 and 2016 SIRS (International Schizophrenia Research Society) Senior Researcher of the Year awards for the most-cited paper in schizophrenia between 2008-2010 and the most downloaded paper in schizophrenia between 2014-2016. Dr. Tandon has received the Exemplary Psychiatrist Award from the National Alliance for Mental Illness on three occasions: in 2009, 2012, and 2015. He was a member of the DSM-5 workgroup on schizophrenia and related psychotic disorders and is a member of the World Psychiatry Association Pharmacopsychiatry Section. Dr. Tandon is currently President of the Florida chapter of the National Alliance for Mental Illness and President-Elect of the Florida Psychiatric Society. His major areas of clinical and research interest are the neuropharmacology of schizophrenia, differences between typical and atypical antipsychotic agents, dimensions of schizophrenic psychopathology (with a particular focus on negative symptoms), neuroendocrine and polysomnographic abnormalities in schizophrenia, and the evidence-based treatment of schizophrenia and other major mental disorders.

Presentation(s):

Send Email for Rajiv Tandon


Assets

Industry-Supported Symposia: Improving Long-Term Outcomes in Schizophrenia: Translating Evidence to Practice



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Industry-Supported Symposia: Improving Long-Term Outcomes in Schizophrenia: Translating Evidence to Practice